Table 1.
Patient characteristics*
| Characteristics | Test | Validation | TCGA | P | P | P |
|---|---|---|---|---|---|---|
| (test vs validation) | (test vs TCGA) | (validation vs TCGA) | ||||
| Total No. | 94 | 92 | 194 | |||
| Age, mean (range), y | 49 (18–73) | 50 (17–66) | 55 (18–88) | .59 | .0002 | .0007 |
| Male sex, No. (%) | 48 (51) | 38 (41) | 54 (28) | .19 | .71 | .06 |
| Bone marrow blasts at diagnosis, mean (range), % | 58 (8–96) | 53 (10–99) | 54 (0–98) | .24 | <.0001 | <.0001 |
| WBC at diagnosis, mean (range), 103/uL | 34 (1–228) | 15 (1–162) | 38 (1–298) | .01 | .18 | <.0001 |
| Cytogenetic risk group, No. (%) | .13 | <.0001 | <.0001 | |||
| Favorable | 3 (3) | 0 (0) | 36 (19) | |||
| Intermediate | 50 (55) | 58 (64) | 113 (59) | |||
| Poor | 38 (42) | 32 (36) | 42 (22) | |||
| Antecedent hematologic disorder, No. (%) | 29 (31) | 9 (10) | NA | .0005 | NA | NA |
| Complete remission rate, No. (%) | 69 (73) | 72 (78) | NA | .5 | NA | NA |
| Overall survival, median (range), mo | 17 (0–72+) | 19 (0–82+) | 12 (0–95+) | .98 | .002 | .002 |
| Mutations, No. (%) | ||||||
| FLT3-ITD | 22 (24) | 12 (14) | 57 (30) | .09 | .26 | .003 |
| FLT3-TKD | 8 (9) | 5 (6) | NA | .57 | NA | NA |
| RAS | 12 (14) | 10 (13) | 11 (6) | .82 | .03 | .08 |
| NPM1 | 21 (24) | 12 (18) | 45 (24) | .43 | 1 | .39 |
| IDH1 | 3 (3) | 5 (5) | 17 (9) | .72 | .13 | .48 |
| IDH2 | 8 (9) | 5 (6) | 17 (9) | .57 | 1 | .48 |
| IDH1/2 | 10 (11) | 10 (12) | 34 (18) | .82 | .16 | .28 |
| DNMT3A | 9 (10) | 12 (13) | 18 (25) | .64 | .02 | .07 |
* The P values were computed from Fisher’s exact test for two-by-two contingency analyses, Mann-Whitney test to compare continuous variables (age, bone marrow blasts at diagnosis, and WBC at diagnosis), and the log-rank test for survival data. All P values were two-tailed, and the threshold of statistical significance was P < .05. NA = not analyzed; WBC = white blood cells; TCGA = the Cancer Genome Atlas.